Walleye Capital LLC Prothena Corp Public LTD CO Transaction History

Walleye Capital LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$19.54 - $26.15 $876,935 - $1.17 Million	44,879 Added 3681.62%	46,098 $951,000
Q1 2024 May 15, 2024	BUY	$24.75 - $40.66 $30,170 - $49,564	1,219 New	1,219 $30,000
Q3 2023 Nov 14, 2023	SELL	$47.3 - $70.6 $2.43 Million - $3.63 Million	-51,366 Reduced 92.3%	4,286 $206,000
Q2 2023 Aug 14, 2023	BUY	$48.26 - $78.59 $2.69 Million - $4.37 Million	55,652 New	55,652 $3.8 Million
Q2 2019 Aug 14, 2019	SELL	$8.85 - $12.49 $64,773 - $91,414	-7,319 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$10.32 - $14.49 $75,532 - $106,052	7,319 New	7,319 $89,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $685M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.